Table 5.

Analysis of association between HPRL and the genetic polymorphisms in patients from risperidone/paliperidone group

Gene	SNP	OR	95% CI Lower bound	95% CI Upper bound	p-value
DRD1	rs4532	0.522	0.216	1.261	0.148
DRD2	rs1076562	0.490	0.192	1.249	0.135
DRD2	rs4245147	1.148	0.519	2.541	0.733
DRD2	rs2283265	0.900	0.301	2.686	0.850
DRD2	rs2734842	0.472	0.187	1.194	0.113
DRD2	rs6277	2.081	0.864	5.011	0.102
DRD2	rs6279	0.434	0.164	1.145	0.092
DRD2	rs1076560	0.969	0.327	2.878	0.955
DRD2/ANKK1	rs2734849	1.833	0.781	4.302	0.164
DRD3	rs11721264	2.042	0.677	6.156	0.205
DRD3	rs2134655	0.659	0.203	2.140	0.488
DRD3	rs963468	0.647	0.251	1.666	0.367
DRD3	rs167771	1.150	0.244	5.414	0.859
DRD3	rs324035	1.719	0.380	7.783	0.482
DRD3	rs167770	1.963	0.622	6.195	0.250
DRD3	rs7633291	2.462	0.640	9.473	0.190
DRD3	rs9817063	1.635	0.626	4.270	0.316
DRD3	rs1587756	2.407	0.489	11.861	0.280
DRD3	rs1800828	2.813	0.739	10.711	0.129
DRD3	rs3773678	1.556	0.326	7.412	0.579
DRD3	rs6280	2.153	0.668	6.947	0.199
DRD4	rs3758653	1.403	0.410	4.806	0.590
DRD4	rs936461	1.500	0.577	3.895	0.405
DRD4	rs11246226	2.421	0.955	6.142	0.063
SLC6A3	rs27048	1.419	0.660	3.054	0.370
SLC6A3	rs3756450	1.373	0.512	3.684	0.529
SLC6A3	rs40184	0.341	0.137	0.852	0.021*
SLC6A3	rs4975646	0.640	0.258	1.589	0.336
SLC6A3	rs2617605	0.880	0.337	2.299	0.794
SLC6A3	rs464049	0.538	0.209	1.384	0.199
SLC6A3	rs1048953	0.823	0.337	2.008	0.668
SLC6A3	rs250686	0.563	0.214	1.482	0.245
SLC6A3	rs3863145	0.362	0.135	0.970	0.043*

Logistic regression analysis was used to test an additive genetic model for association between HPRL and the polymorphisms in adjusting for age, sex and CPZeq. OR – odds ratio; CI – lower and upper bound 95% confidence intervals. ORs are reported for the risk of HPRL attributable to the rare allele vs common allele

*Values are deemed to have significance